## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID AFFR	OVAL
OMB Number:	3235-0287
Estimated average bu	rden

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Name and Address of Reporting Person*     El-Hibri Fuad					2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner														
(Last) (First) (Middle) 400 PROFESSIONAL DRIVE, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2016  X Officer (give title below) Chairman  Chairman															
(Street) GAITHERSBURG MD 20879				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Application)  X Form filed by One Reporting Person  Form filed by More than One Reporting				n		
(City)	(S	tate)	(Zip)												Person		c triari	TOTIC TROPOL	ung
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Ye		Execution Date,		on Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a					es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				,
Common	Stock			05/23	05/23/2016				M <sup>(1)</sup>		20,000	A	\$15.91		1,719,073		D		
Common	Stock			05/23	3/2016				<b>S</b> <sup>(1)</sup>		20,000	D	\$42.7	42.76 <sup>(2)</sup> 1,6		1,699,073		D	
Common	Stock			05/23	05/23/2016				S <sup>(1)</sup>		25,000	D	\$42.5		1,674,073		D		
Common Stock		05/24/2016		6		M <sup>(1)</sup>		20,000	A	\$15	\$15.91		1,694,073		D				
Common	Stock			05/24/2016		5		S <sup>(1)</sup>		20,000	D	\$42.2	\$42.26 <sup>(3)</sup>		1,674,073		D		
Common	Stock			05/25/2016					M <sup>(1)</sup>		20,000	A	\$15	.91	1,694,073			D	
Common Stock			05/25	5/2016				S <sup>(1)</sup>		20,000	D \$42.57 <sup>(</sup>		57 <sup>(4)</sup>	1,674,073			D		
Common Stock													2,350,331 <sup>(5)</sup>			I :	By Intervac, L.L.C.		
Common Stock														1,524,155(6)			I .	By Biovac, L.L.C.	
		-	Γable ΙΙ -								osed of,				wned				
						call	_				convertik			_	-: .		. 1		1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution if any			ction Instr.	on of		6. Date Exercisa Expiration Date (Month/Day/Yea		te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		y De Se (In	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amour or Numbe of Shares	er					
Employee Stock Option (right to buy)	\$15.91	05/23/2016			M <sup>(1)</sup>			20,000	(7)		03/08/2017	Common Stock	20,00	00	\$0.00	64,594	4	D	
Employee Stock Option (right to buy)	\$15.91	05/24/2016			M <sup>(1)</sup>			20,000	(7)		03/08/2017	Common Stock	20,00	00	\$0.00	44,594	4	D	
Employee Stock Option (right to buy)	\$15.91	05/25/2016			M <sup>(1)</sup>			20,000	(7)		03/08/2017	Common Stock	20,00	00	\$0.00	24,594	4	D	

## **Explanation of Responses:**

- 1. The transactions reported herein were effectuated by the Reporting Person pursuant to two separate trading plans adopted on February 29, 2016, each of which are intended to comply with Rule 10b5-1(c) under the Exchange Act.
- 2. The selling price of \$42.76 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from \$42.29 to \$42.85, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 3. The selling price of \$42.26 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from \$41.58 to \$42.49, inclusive.

The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

- 4. The selling price of \$42.57 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from \$42.15 to \$42.93, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 5. Mr. El-Hibri's holdings through Intervac, L.L.C. include 1,638,403 shares of Common Stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts.
- 6. Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
- 7. The options vested in three equal installments on March 9, 2011, March 9, 2012 and March 9, 2013.

## Remarks:

/s/ Carl A. Valenstein, attorneyin-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.